Detailed information for compound 430602

Basic information

Technical information
  • TDR Targets ID: 430602
  • Name: 5-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phe nyl]-5-methylpyrrol-1-yl]-2-methylbenzoic aci d
  • MW: 449.901 | Formula: C26H21ClFNO3
  • H donors: 1 H acceptors: 2 LogP: 6.47 Rotable bonds: 6
    Rule of 5 violations (Lipinski): 1
  • SMILES: Clc1ccc(c(c1)c1ccc(n1c1ccc(c(c1)C(=O)O)C)C)OCc1ccc(cc1)F
  • InChi: 1S/C26H21ClFNO3/c1-16-3-10-21(14-22(16)26(30)31)29-17(2)4-11-24(29)23-13-19(27)7-12-25(23)32-15-18-5-8-20(28)9-6-18/h3-14H,15H2,1-2H3,(H,30,31)
  • InChiKey: YNGYDYOYWOAUDY-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 5-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-pyrrol-1-yl]-2-methyl-benzoic acid
  • 5-[2-[5-chloro-2-[(4-fluorophenyl)methoxy]phenyl]-5-methyl-1-pyrrolyl]-2-methylbenzoic acid
  • 5-[2-[5-chloro-2-(4-fluorobenzyl)oxy-phenyl]-5-methyl-pyrrol-1-yl]-2-methyl-benzoic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens prostaglandin E receptor 4 (subtype EP4) Starlite/ChEMBL References
Homo sapiens prostaglandin F receptor (FP) Starlite/ChEMBL References
Homo sapiens prostaglandin I2 (prostacyclin) receptor (IP) Starlite/ChEMBL References
Homo sapiens prostaglandin E receptor 3 (subtype EP3) Starlite/ChEMBL References
Homo sapiens prostaglandin E receptor 2 (subtype EP2), 53kDa Starlite/ChEMBL References
Homo sapiens thromboxane A2 receptor Starlite/ChEMBL References
Homo sapiens prostaglandin E receptor 1 (subtype EP1), 42kDa Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Trypanosoma cruzi hypothetical protein, conserved 0.091 0.2691 1
Echinococcus granulosus fatty acid amide hydrolase 1 0.2546 1 1
Mycobacterium tuberculosis Probable amidase AmiB2 (aminohydrolase) 0.0307 0 0.5
Trypanosoma brucei lipase domain protein, putative 0.091 0.2691 1
Trichomonas vaginalis lipase containing protein, putative 0.091 0.2691 0.5
Mycobacterium ulcerans peptide amidase, GatA 0.0307 0 0.5
Mycobacterium ulcerans amidase 0.0307 0 0.5
Mycobacterium tuberculosis Possible amidase (aminohydrolase) 0.0307 0 0.5
Wolbachia endosymbiont of Brugia malayi aspartyl/glutamyl-tRNA amidotransferase subunit A 0.0307 0 0.5
Chlamydia trachomatis glutamyl-tRNA(Gln) amidotransferase subunit A 0.0307 0 0.5
Leishmania major hypothetical protein, conserved 0.091 0.2691 1
Echinococcus granulosus fatty acid amide hydrolase 1 0.2546 1 1
Mycobacterium tuberculosis Probable amidase AmiD (acylamidase) (acylase) 0.0307 0 0.5
Mycobacterium ulcerans amidase 0.0307 0 0.5
Loa Loa (eye worm) lipase 0.091 0.2691 0.2691
Mycobacterium ulcerans aspartyl/glutamyl-tRNA amidotransferase subunit A 0.0307 0 0.5
Echinococcus multilocularis sn1 specific diacylglycerol lipase beta 0.091 0.2691 0.2691
Plasmodium vivax glutamyl-tRNA(Gln) amidotransferase subunit A, putative 0.0307 0 0.5
Trichomonas vaginalis lipase containing protein, putative 0.091 0.2691 0.5
Mycobacterium ulcerans amidase 0.0307 0 0.5
Mycobacterium leprae PROBABLE GLUTAMYL-TRNA(GLN) AMIDOTRANSFERASE (SUBUNIT A) GATA (Glu-ADT SUBUNIT A) 0.0307 0 0.5
Echinococcus granulosus sn1 specific diacylglycerol lipase beta 0.091 0.2691 0.2691
Loa Loa (eye worm) hypothetical protein 0.2546 1 1
Echinococcus multilocularis fatty acid amide hydrolase 1 0.2546 1 1
Plasmodium falciparum glutamyl-tRNA(Gln) amidotransferase subunit A 0.0307 0 0.5
Trypanosoma cruzi hypothetical protein, conserved 0.091 0.2691 1
Schistosoma mansoni amidase 0.2546 1 1
Treponema pallidum aspartyl/glutamyl-tRNA amidotransferase subunit A 0.0307 0 0.5
Echinococcus multilocularis fatty acid amide hydrolase 1 0.2546 1 1
Mycobacterium tuberculosis Probable amidase AmiC (aminohydrolase) 0.0307 0 0.5
Mycobacterium tuberculosis Probable amidase AmiA2 (aminohydrolase) 0.0307 0 0.5
Brugia malayi Lipase family protein 0.091 0.2691 0.2691
Onchocerca volvulus 0.091 0.2691 0.5
Mycobacterium ulcerans amidase 0.0307 0 0.5
Trypanosoma brucei lipase domain protein, putative 0.091 0.2691 1
Schistosoma mansoni fatty-acid amide hydrolase 0.2546 1 1
Mycobacterium ulcerans amidase 0.0307 0 0.5
Mycobacterium leprae PROBABLE AMIDASE AMIC (AMINOHYDROLASE) 0.0307 0 0.5

Activities

Activity type Activity value Assay description Source Reference
Activity (functional) = 75 % Reversal of hypersensitivity in FCA rat model of inflammatory pain at 5 mg/kg, po ChEMBL. 17175160
AUC/dose (ADMET) = 18 min.kg/L Normalized AUC (0 to t) in rat at 3 mg/kg, po ChEMBL. 17175160
CL (ADMET) = 22 ml/min.kg Blood clearance in rat at 1 mg/kg, iv or 3 mg/kg, po ChEMBL. 17175160
CL (ADMET) <= 3.6 ml/min/g Intrinsic clearance in rat liver microsomes ChEMBL. 17175160
CL (ADMET) <= 3.6 ml/min/g Intrinsic clearance in monkey liver microsomes ChEMBL. 17175160
CL (ADMET) <= 3.6 ml/min/g Intrinsic clearance in human liver microsomes ChEMBL. 17175160
CL (ADMET) <= 3.6 ml/min/g Intrinsic clearance in dog liver microsomes ChEMBL. 17175160
Cmax (ADMET) = 0.59 uM Cmax in rat at 3 mg/kg, po ChEMBL. 17175160
Drug uptake (ADMET) = 0.031 uM Drug level in brain of rat FCA model of inflammatory pain at 30 mg/kg, po after 24 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 0.037 uM Drug level in blood of rat FCA model of inflammatory pain at 30 mg/kg, po after 20 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 0.753 uM Drug level in brain of rat FCA model of inflammatory pain at 30 mg/kg, po after 8 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 0.913 uM Drug level in brain of rat FCA model of inflammatory pain at 30 mg/kg, po after 6 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 1.221 uM Drug level in brain of rat FCA model of inflammatory pain at 30 mg/kg, po after 4 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 1.6 uM Drug level in blood of rat FCA model of inflammatory pain at 30 mg/kg, po after 8 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 2.309 uM Drug level in blood of rat FCA model of inflammatory pain at 30 mg/kg, po after 6 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 2.484 uM Drug level in brain of rat FCA model of inflammatory pain at 30 mg/kg, po after 2 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 2.598 uM Drug level in brain of rat FCA model of inflammatory pain at 30 mg/kg, po after 0.25 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 3.561 uM Drug level in blood of rat FCA model of inflammatory pain at 30 mg/kg, po after 4 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 3.564 uM Drug level in brain of rat FCA model of inflammatory pain at 30 mg/kg, po after 1 hr ChEMBL. 17175160
Drug uptake (ADMET) = 5.93 uM Drug level in blood of rat FCA model of inflammatory pain at 30 mg/kg, po after 2 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 7.358 uM Drug level in blood of rat FCA model of inflammatory pain at 30 mg/kg, po after 0.25 hrs ChEMBL. 17175160
Drug uptake (ADMET) = 10.089 uM Drug level in blood of rat FCA model of inflammatory pain at 30 mg/kg, po after 1 hr ChEMBL. 17175160
ED50 (functional) = 2.5 mg kg-1 Reversal of hypersensitivity in po dosed FCA rat model of inflammatory pain ChEMBL. 17175160
F (ADMET) = 45 % Bioavailability in rat at 3 mg/kg, po ChEMBL. 17175160
IC50 (binding) = -8.3 Displacement of [3H]PGE2 from human recombinant EP1 receptor expressed in CHOK1 cell membrane ChEMBL. 17175160
IC50 (functional) = -7.4 Inhibition of human recombinant TP receptor expressed in CHO cells by calcium mobilisation assay ChEMBL. 17175160
IC50 (functional) < -5.5 Inhibition of human recombinant FP receptor expressed in CHO cells by calcium mobilisation assay ChEMBL. 17175160
IC50 (functional) < -5.5 Inhibition of human recombinant EP2 receptor expressed in CHO cells up to 1 uM by calcium mobilisation assay ChEMBL. 17175160
IC50 (functional) < -5.5 Inhibition of human recombinant IP receptor expressed in CHO cells up to 1 uM by calcium mobilisation assay ChEMBL. 17175160
IC50 (binding) = -4.8 Binding affinity to human EP4 receptor expressed in CHO cells ChEMBL. 17175160
Ki (functional) = -9 Inhibition of human recombinant EP1 receptor expressed in CHO cells by calcium mobilisation assay ChEMBL. 17175160
Ki (functional) = -7.8 Inhibition of human recombinant TP receptor expressed in CHO cells by calcium mobilisation assay ChEMBL. 17175160
Ki (functional) = -6.3 Inhibition of human recombinant EP3 receptor expressed in CHO cells by calcium mobilisation assay ChEMBL. 17175160
Ki (functional) = -5.2 Inhibition of human EP4 recombinant receptor expressed in CHO cells by cAMP mobilisation assay ChEMBL. 17175160
Ki (binding) = -5.1 Binding affinity to human EP4 receptor expressed in CHO cells ChEMBL. 17175160
Log IC50 (binding) = 4.8 Binding affinity to human EP4 receptor expressed in CHO cells ChEMBL. 17175160
Log IC50 (functional) < 5.5 Inhibition of human recombinant FP receptor expressed in CHO cells by calcium mobilisation assay ChEMBL. 17175160
Log IC50 (functional) < 5.5 Inhibition of human recombinant EP2 receptor expressed in CHO cells up to 1 uM by calcium mobilisation assay ChEMBL. 17175160
Log IC50 (functional) < 5.5 Inhibition of human recombinant IP receptor expressed in CHO cells up to 1 uM by calcium mobilisation assay ChEMBL. 17175160
Log IC50 (functional) = 7.4 Inhibition of human recombinant TP receptor expressed in CHO cells by calcium mobilisation assay ChEMBL. 17175160
Log IC50 (binding) = 8.3 Displacement of [3H]PGE2 from human recombinant EP1 receptor expressed in CHOK1 cell membrane ChEMBL. 17175160
Log Ki (binding) = 5.1 Binding affinity to human EP4 receptor expressed in CHO cells ChEMBL. 17175160
Log Ki (functional) = 5.2 Inhibition of human EP4 recombinant receptor expressed in CHO cells by cAMP mobilisation assay ChEMBL. 17175160
Log Ki (functional) = 6.3 Inhibition of human recombinant EP3 receptor expressed in CHO cells by calcium mobilisation assay ChEMBL. 17175160
Log Ki (functional) = 7.8 Inhibition of human recombinant TP receptor expressed in CHO cells by calcium mobilisation assay ChEMBL. 17175160
Log Ki (functional) = 9 Inhibition of human recombinant EP1 receptor expressed in CHO cells by calcium mobilisation assay ChEMBL. 17175160
Ratio (ADMET) = 0.4 Ratio of drug level in brain to blood in rat FCA model of inflammatory pain at 30 mg/kg, po after 0.25 hrs ChEMBL. 17175160
Ratio (ADMET) = 0.4 Ratio of drug level in brain to blood in rat FCA model of inflammatory pain at 30 mg/kg, po after 1 hr ChEMBL. 17175160
Ratio (ADMET) = 0.4 Ratio of drug level in brain to blood in rat FCA model of inflammatory pain at 30 mg/kg, po after 2 hrs ChEMBL. 17175160
Ratio (ADMET) = 0.4 Ratio of drug level in brain to blood in rat FCA model of inflammatory pain at 30 mg/kg, po after 4 hrs ChEMBL. 17175160
Ratio (ADMET) = 0.4 Ratio of drug level in brain to blood in rat FCA model of inflammatory pain at 30 mg/kg, po after 6 hrs ChEMBL. 17175160
Ratio (ADMET) = 0.4 Ratio of drug level in brain to blood in rat FCA model of inflammatory pain at 30 mg/kg, po after 8 hrs ChEMBL. 17175160
Ratio (ADMET) = 0.5 Ratio of drug level in brain to blood in rat FCA model of inflammatory pain at 30 mg/kg, po after 24 hrs ChEMBL. 17175160
t1/2 (ADMET) = 4.6 hr Half life in rat at 1 mg/kg, iv or 3 mg/kg, po ChEMBL. 17175160
Tmax (ADMET) = 0.5 hr Tmax in rat at 3 mg/kg, po ChEMBL. 17175160
Vss (ADMET) = 2.6 L/Kg Volume of distribution in rat at 1 mg/kg, iv or 3 mg/kg, po ChEMBL. 17175160

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.